Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study

BACKGROUND AND AIMS: With distinct mechanisms of action, the combination of tropifexor (TXR) and cenicriviroc (CVC) may provide an effective treatment for NASH. This randomized, multicenter, double-blind, phase 2b study assessed the safety and efficacy of TXR and CVC combination, compared with respe...

Descripción completa

Detalles Bibliográficos
Autores principales: Anstee, Quentin M., Lucas, Kathryn J., Francque, Sven, Abdelmalek, Manal F., Sanyal, Arun J., Ratziu, Vlad, Gadano, Adrian C., Rinella, Mary, Charlton, Michael, Loomba, Rohit, Mena, Edward, Schattenberg, Jörn M., Noureddin, Mazen, Lazas, Donald, Goh, George B.B., Sarin, Shiv K., Yilmaz, Yusuf, Martic, Miljen, Stringer, Rowan, Kochuparampil, Jossy, Chen, Li, Rodriguez-Araujo, Gerardo, Chng, Elaine, Naoumov, Nikolai V., Brass, Clifford, Pedrosa, Marcos C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles: Steatohepatitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521801/
https://www.ncbi.nlm.nih.gov/pubmed/37162151
http://dx.doi.org/10.1097/HEP.0000000000000439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521801/
https://www.ncbi.nlm.nih.gov/pubmed/37162151
http://dx.doi.org/10.1097/HEP.0000000000000439

Ejemplares similares